How to Get Dayvigo (Lemborexant) in South Dakota

What Is Dayvigo and Why South Dakota Patients Seek It

Dayvigo is a dual orexin receptor antagonist that blocks both OX1R and OX2R, reducing the wake-promoting signal rather than broadly sedating the central nervous system. That targeted mechanism distinguishes it from older benzodiazepines and Z-drugs. South Dakota patients increasingly ask about Dayvigo because primary care providers in rural areas may be less familiar with newer Schedule IV sleep agents, making telehealth a practical route to access.

Lemborexant received FDA approval on December 20, 2019, for adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both. The FDA prescribing information lists 5 mg as the starting dose, with 10 mg permitted if the lower dose is tolerated but insufficiently effective. [1]

The SUNRISE-1 trial, published in JAMA Network Open (2019, N=291 patients), compared lemborexant 5 mg, lemborexant 10 mg, and placebo over a 30-day treatment period. Lemborexant 10 mg reduced mean subjective sleep onset latency (sSOL) by 17.7 minutes compared with placebo (P<0.001), and lemborexant 5 mg reduced sSOL by 15.0 minutes compared with placebo (P<0.001). [2] Both doses also improved wake after sleep onset (WASO) significantly versus placebo, a finding relevant for patients whose chief complaint is middle-of-the-night waking rather than trouble falling asleep.

SUNRISE-2, a 12-month maintenance study, confirmed durable efficacy. At 6 months, lemborexant 10 mg maintained a statistically significant reduction in LPS (latency to persistent sleep) of 17.0 minutes versus placebo (P<0.001), establishing that tolerance to the drug's sleep-promoting effect does not appear to develop over a year of nightly use. [3]

South Dakota has no state law that restricts DORA prescribing beyond the federal Controlled Substances Act Schedule IV framework. [4] Any licensed SD prescriber with DEA registration may write for lemborexant.

South Dakota Telehealth Rules for Controlled Substances

South Dakota permits telehealth prescribing of Schedule IV controlled substances without a mandatory in-person visit, provided the provider establishes a valid patient-provider relationship. South Dakota Codified Law 36-4-44 defines that relationship as including a synchronous audio-video evaluation. [5] A phone-only visit does not satisfy the requirement under current SD telemedicine statute.

Federal law also applies. Under the DEA's Ryan Haight Act framework, Schedule IV substances prescribed via telemedicine ordinarily require the patient to have had at least one in-person medical evaluation. The DEA issued a temporary telemedicine exemption during the COVID-19 public health emergency that expired May 11, 2023. A subsequent DEA proposed rule would have reinstated stricter requirements, but as of mid-2025 the DEA's final telemedicine rule remains under review, and telemedicine prescribing of Schedule IV substances continues under existing DEA registration for many platforms. [6] Patients should confirm their chosen platform's compliance posture before scheduling.

Sleep medicine-focused telemedicine platforms operating in South Dakota include multi-state practices licensed in SD that conduct video visits, review sleep history, and transmit e-prescriptions to South Dakota retail pharmacies or mail-order pharmacies. The American Academy of Sleep Medicine (AASM) supports the use of telemedicine in sleep medicine when providers conduct a structured clinical interview and, where indicated, review prior polysomnography or home sleep apnea test results. [7]

A key practical point: because lemborexant is a Schedule IV drug, most telehealth platforms in South Dakota will send an e-prescription directly to a retail pharmacy using DEA-compliant e-prescribing of controlled substance (EPCS) software. Paper prescriptions can also be mailed, though that adds 3 to 5 business days.

Step-by-Step: How to Get a Dayvigo Prescription in South Dakota

Getting Dayvigo in South Dakota follows a predictable sequence regardless of whether you use an in-person provider or a telehealth service.

Step 1. Choose your prescriber pathway. Options include your South Dakota primary care physician, a board-certified sleep medicine specialist (the nearest AASM-accredited center in SD is at Sanford USD Medical Center in Sioux Falls), [8] or a telehealth platform licensed in South Dakota.

Step 2. Prepare your sleep history. Bring or describe the duration of insomnia (the FDA label requires adult-onset insomnia), prior treatments tried (over-the-counter antihistamines, melatonin, Z-drugs, benzodiazepines), any sleep study results, and comorbid conditions such as obstructive sleep apnea or depression. Most insurers require documented CBT-I failure or concurrent CBT-I enrollment before they will authorize a DORA. [9]

Step 3. Complete a video or in-person evaluation. The clinician will screen for contraindications including narcolepsy (lemborexant is contraindicated in narcolepsy per the FDA label) [1], severe hepatic impairment, concurrent CNS depressant use, and complex sleep behavior history. They will also confirm that no other underlying sleep disorder explains the insomnia.

Step 4. Receive and fill the e-prescription. South Dakota retail pharmacies that stock Schedule IV drugs can dispense lemborexant. Not every small-town SD pharmacy carries it; calling ahead saves a trip. If a local pharmacy does not stock it, mail-order pharmacies licensed in South Dakota can ship it within 2 to 3 business days.

Step 5. Manage prior authorization if required. See the dedicated section below for commercial insurance PA requirements.

No routine laboratory testing is mandated by the FDA label before starting lemborexant. [1] Liver function tests may be ordered clinically if the patient has known hepatic disease, because lemborexant exposure increases substantially in moderate hepatic impairment (a 2.3-fold increase in AUC per the FDA label). [1]

Who Can Prescribe Dayvigo in South Dakota

South Dakota authorizes four prescriber categories to write Schedule IV controlled substance prescriptions.

Medical doctors (MD) and osteopathic physicians (DO) with an active South Dakota medical license and DEA registration may prescribe lemborexant without restriction beyond standard controlled substance rules. [4]

Nurse practitioners (NP) in South Dakota hold prescriptive authority for Schedule IV drugs under SDCL 36-9A-16, provided they maintain a current DEA registration. South Dakota requires NPs to have a collaborative agreement with a physician for prescriptive authority. [10] That agreement does not require the collaborating physician to cosign each prescription; it is a practice-level document.

Physician assistants (PA) in South Dakota may also prescribe Schedule IV substances under SDCL 36-4A-10, within the scope of their supervising physician agreement. [11]

Dentists and optometrists may not prescribe sleep medications in South Dakota; their scope does not cover chronic insomnia management.

Prior Authorization: What South Dakota Commercial Insurers Require

Prior authorization (PA) is common for Dayvigo across commercial plans in South Dakota. The specific PA criteria vary by payer, but a synthesis of publicly available formulary policies shows a consistent pattern.

Most South Dakota commercial plans require documentation of all of the following before approving Dayvigo:

1. A diagnosis of chronic insomnia disorder (symptom frequency at least 3 nights per week for at least 3 months), consistent with DSM-5 criteria. [12]
2. Trial and failure of at least one first-line agent, typically a Z-drug (zolpidem, eszopiclone, or zaleplon) or a low-dose doxepin, at an adequate dose for at least 4 weeks.
3. Documentation of CBT-I attempt or concurrent enrollment. The American College of Physicians (ACP) 2016 guideline recommends CBT-I as first-line treatment for chronic insomnia disorder in adults. [13]
4. Attestation that the patient does not have narcolepsy.

The HealthRX clinical team has developed a practical PA submission framework for Dayvigo in South Dakota. When a prescriber submits the initial PA, including the four elements above plus a clinical note explicitly listing each prior agent by generic name, dose, duration, and reason for discontinuation, approval rates increase compared with submissions that list only diagnosis codes. Payers reviewing PA requests look for specificity; "failed zolpidem" is less persuasive than "zolpidem tartrate 10 mg nightly for 8 weeks, discontinued due to next-morning drowsiness and two near-falls." Attaching a brief sleep diary or an Insomnia Severity Index (ISI) score above 14 (moderate-to-severe range) further supports medical necessity. [14]

If the initial PA is denied, South Dakota's prompt pay and external review laws under SDCL 58-17J allow patients to request an independent external review within 4 months of denial. [15]

South Dakota Medicaid and Dayvigo Coverage

South Dakota Medicaid does not cover Dayvigo as of July 2025. The South Dakota Medicaid preferred drug list does not include lemborexant, and no prior authorization pathway currently exists to obtain coverage through the Medicaid fee-for-service program. [16]

Medicaid beneficiaries in South Dakota who need treatment for chronic insomnia are directed toward covered agents. Trazodone (off-label, widely used), doxepin 3 mg and 6 mg (FDA-approved for sleep maintenance insomnia), and zolpidem are on the SD Medicaid formulary. [16]

For patients without coverage, the Eisai patient assistance program (Eisai's Patient Assistance Program, sometimes called the Eisai Assistance Program) may provide lemborexant at no cost to qualifying individuals with household incomes below 400% of the federal poverty level. Patients can apply directly through Eisai's website or ask their prescriber's office to submit the application. The NeedyMeds database lists this program and provides an updated eligibility threshold annually. [17]

The retail cash price for a 30-tablet supply of lemborexant 10 mg ranges from approximately $380 to $420 at South Dakota retail pharmacies as of mid-2025 (GoodRx and NeedyMeds price listings). A manufacturer copay card, available to commercially insured patients, may reduce the copay to as low as $5 per 30-day fill for eligible patients. [18]

Pharmacy Access in South Dakota: Retail and Mail-Order Options

South Dakota has 350 to 400 licensed retail pharmacies statewide, concentrated in Sioux Falls, Rapid City, Aberdeen, and Brookings. Rural areas, particularly the western SD counties near the Black Hills, may have pharmacies that do not routinely stock Schedule IV sleep agents with lower prescription volume. [19]

Lemborexant is commercially available only as the brand Dayvigo. No FDA-approved generic exists as of July 2025. [1] The patent protection for lemborexant does not expire until approximately 2036 based on the US patent filing timeline, so generic availability in South Dakota is not imminent.

503A compounding pharmacies in South Dakota may compound preparations that are essentially copies of a commercially available drug only under narrow circumstances. The FDA's position, stated in its 503A guidance documents, is that compounding a drug that is commercially available is generally not permitted because it would not meet the "not commercially available" requirement of 21 U.S.C. 503A. [20] Lemborexant's active moiety is commercially available as Dayvigo; therefore, a 503A pharmacy in South Dakota cannot legally compound lemborexant for individual patients except in cases where the patient has a documented allergy to an inactive ingredient in the commercial product and the compounded version addresses that specific need. Patients who have been told that a compounding pharmacy can supply "compounded lemborexant" at a lower cost should ask the pharmacy to produce its 503A exemption documentation.

Mail-order pharmacy is the most practical solution for many rural South Dakota patients. National mail-order pharmacies including those affiliated with Express Scripts, CVS Caremark, and OptumRx are licensed in South Dakota and can ship Dayvigo. Fill time is typically 2 to 3 business days from prescription receipt for established patients, and up to 5 business days for first fills that require identity verification under controlled substance shipping rules.

Clinical Pharmacology: What South Dakota Patients Should Know Before Starting

Understanding how lemborexant works helps patients set accurate expectations. Orexin (also called hypocretin) is a neuropeptide produced in the lateral hypothalamus that promotes wakefulness. [21] In individuals with chronic insomnia, orexin signaling remains active when it should attenuate at night, prolonging wake time. Lemborexant competitively antagonizes both OX1R and OX2R, reducing that signal without globally suppressing CNS activity.

The drug reaches peak plasma concentration (Tmax) in approximately 1 to 3 hours under fasted conditions. [1] Taking lemborexant with or shortly after a high-fat meal delays Tmax by approximately 2 hours and may reduce Cmax, so the FDA label recommends taking it on an empty stomach or after a light snack for fastest effect. [1]

Half-life is approximately 17 to 19 hours. [1] That relatively long half-life means that next-morning impairment is a real concern, particularly at the 10 mg dose, in older adults, and in patients who take the drug with fewer than 7 hours available for sleep. The prescribing information includes a boxed warning about complex sleep behaviors (sleepwalking, sleep driving) and a warning about next-day driving impairment. [1] Patients must be counseled not to drive until they know how lemborexant affects their morning alertness.

Alcohol and other CNS depressants potentiate lemborexant's sedative effect. [1] CYP3A4 inhibitors (such as fluconazole, clarithromycin, or grapefruit juice taken regularly) increase lemborexant exposure; strong CYP3A4 inhibitors are contraindicated with lemborexant per the FDA label. [1] CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce lemborexant plasma levels significantly and should be avoided. [1]

A 2022 network meta-analysis published in the British Journal of Clinical Pharmacology (N=31 RCTs, 12,350 patients) ranked lemborexant 10 mg among the most effective agents for both sleep onset and sleep maintenance outcomes while producing lower morning-after residual sedation than suvorexant 20 mg, the other FDA-approved DORA. [22] Lemborexant showed a standardized mean difference of -0.87 (95% CI -1.12 to -0.62) versus placebo for sleep onset latency reduction, outperforming zolpidem 10 mg (-0.74 to 95% CI -0.95 to -0.53) and eszopiclone 3 mg (-0.70 to 95% CI -0.91 to -0.49) in the same analysis. [22]

Older adults represent a population of particular interest in South Dakota, where 16.9% of residents are aged 65 or older per 2020 census data. [23] In the SUNRISE-2 trial, the subset of adults aged 65 and older showed meaningful improvements in subjective sleep quality with both doses of lemborexant, and the drug did not produce significant residual sedation as measured by next-morning driving simulation at the 5 mg dose. [3] The 10 mg dose did show mild residual effects in this age group, leading most sleep medicine clinicians to start older adults on 5 mg. [7]

Transferring an Existing Dayvigo Prescription to South Dakota

Patients who move to South Dakota from another state with an active lemborexant prescription face a procedural step. Because lemborexant is a Schedule IV controlled substance, federal law (21 CFR 1306.25) permits a Schedule IV prescription to be transferred between pharmacies once. [24] The transfer must occur pharmacy-to-pharmacy, meaning the patient cannot physically transport the written prescription; the pharmacist at the receiving South Dakota pharmacy calls or electronically transfers the prescription from the original pharmacy.

If the prescription was issued by an out-of-state prescriber who is not licensed in South Dakota, the prescription remains technically valid at a South Dakota pharmacy for a Schedule IV drug because federal law governs the validity of the prescription itself, not the state where the prescriber is licensed, as long as the prescriber held DEA registration at the time of issuance. In practice, some South Dakota pharmacies apply more conservative policies and prefer that the patient establish care with a South Dakota-licensed provider before dispensing refills. Confirming this with the pharmacy before the transfer avoids delays.

An out-of-state telehealth provider licensed in South Dakota may issue a new prescription, which restarts the refill count and ensures no interruption of supply during the transition. Patients should plan for at least a 7 to 10 day lead time when transferring care.

Setting Expectations: Timeline From First Contact to First Dose

A South Dakota patient starting fresh with no prior insomnia treatment can expect the following timeline.

Telehealth visit scheduling for sleep-focused platforms is typically available within 1 to 5 business days in South Dakota. The video visit itself takes 20 to 40 minutes. If the provider writes a prescription immediately and sends it electronically, a Sioux Falls or Rapid City pharmacy with stock can fill it the same day. Rural pharmacies or those without stock require 1 to 3 additional days for a special order. Mail-order delivery adds 2 to 5 business days.

Total realistic time from first contact to first dose: 3 to 7 days for urban South Dakota patients, and 5 to 12 days for those in rural western SD counties using mail-order.

Prior authorization, if required, adds 3 to 10 business days for initial review. Urgent PA requests (documented severe insomnia with safety concerns) may be reviewed within 72 hours under South Dakota's prompt review requirements for urgent clinical situations under SDCL 58-17J. [15]